Company facts
- Headquarters
- Washington, District of Columbia
- Most recent report
- 8-K, filed Aug 3, 2026
- Incorporated
- Delaware
- Filings on record
- 1,007+ filings
- On EDGAR
- CIK 313616
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 26
News 8 of 80
Prospectuses and Registrations 8 of 31
- S-8 Registration statement for an employee plan Jun 9, 2026
- S-8 Registration statement for an employee plan Jun 9, 2026
- 424B5 Prospectus supplement for an offering Apr 23, 2026
- FWP Free writing prospectus Apr 22, 2026
- 424B5 Prospectus supplement for an offering Apr 22, 2026
- 25-NSE Notice that a security was delisted Mar 18, 2026
- S-3ASR Automatic shelf registration Apr 1, 2024
- 25-NSE Notice that a security was delisted Apr 1, 2024
Proxies 8 of 18
- DEFA14A Extra proxy material Mar 25, 2026
- DEF 14A Proxy statement for a shareholder vote Mar 25, 2026
- DEFA14A Extra proxy material Mar 26, 2025
- DEF 14A Proxy statement for a shareholder vote Mar 26, 2025
- PX14A6G Shareholder's own proxy material Apr 12, 2024
- DEFA14A Extra proxy material Mar 27, 2024
- DEF 14A Proxy statement for a shareholder vote Mar 27, 2024
- PX14A6G Shareholder's own proxy material Apr 7, 2023
Ownership 8 of 807
- 4 Insider reported a trade Aug 24, 2026
- 144 Notice of a proposed sale of restricted stock Aug 21, 2026
- 4 Insider reported a trade Aug 6, 2026
- 4 Insider reported a trade Aug 6, 2026
- 4 Insider reported a trade Aug 6, 2026
- 4 Insider reported a trade Aug 6, 2026
- 4 Insider reported a trade Aug 6, 2026
- 4 Insider reported a trade Aug 6, 2026
Other 8 of 45
- 11-K Employee stock plan report Jun 16, 2026
- SD Conflict minerals disclosure May 12, 2026
- CERT Exchange certified a listing Apr 30, 2026
- 8-A12B Registration of a security for exchange listing Apr 29, 2026
- ARS Annual report sent to shareholders Mar 25, 2026
- DFAN14A Feb 27, 2026
- DFAN14A Feb 17, 2026
- 11-K Employee stock plan report Jun 17, 2025
What to read: Jun 2026 10-Q
SECSift found 2 of 15 sections worth reading, with 1 positive, 9 notable, and 4 negative flags.
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
Masimo acquisition closed; debt surged; major litigation; segment results.Notable- June 10, 2026: closed Masimo acquisition for ~$9.8B cash, financed with debt and cash on hand.
- Preliminary goodwill recorded: $4.96B from Masimo. Total goodwill now $47.4B.
- New $5B 364-day facility entered April 16, 2026, with leverage covenant (0.65x). No borrowings drawn.
- Hawkins securities class action settlement preliminarily approved; $0 impact expected due to insurance.
- Masimo's former CEO Kiani seeks ~$35M cash plus 2.7M shares in severance dispute; multiple related suits.
Item 2
Masimo acquisition just closed; core growth modest at 3%; segment margins diverge sharply.Notable- Operating profit margin +520bps to 18.0%, almost entirely from non-repeating 2025 impairment of 730bps.
- Life Sciences operating profit swung from -$239M loss to $244M profit; prior year had $432M trade name impairment.
- Q2 2026 effective tax rate 19.3%; net discrete charges $21M from prior-period tax positions.
- Comprehensive income fell $930M in Q2 due to $149M FX translation loss vs $1.0B gain in Q2 2025.
What changed: Jun 2026 vs. Mar 2026
About 24% of DHR's Jun 2026 10-Q is new information. 89 paragraphs were added, 134 changed, and 29 removed. Below are the most important lines SECSift identified.
New
Changed
Everything here comes from Danaher Corp's own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Aug 19, 2026, from the 10-Q for Jun 2026.